University of Pennsylvania, Philadelphia, PA.
Veterinary Specialists of Alaska, Anchorage, AK.
Vet Pathol. 2023 Nov;60(6):849-856. doi: 10.1177/03009858231174452. Epub 2023 May 24.
Cutaneous mastocytosis (CM) is a rare condition in young dogs characterized by multicentric cutaneous proliferation of neoplastic mast cells. Clinical data from 8 dogs that met inclusion criteria (age of onset less than 1.5 years, greater than 3 lesions) were obtained via a standardized survey. Biopsy samples were classified by the Kiupel/Patnaik grading systems and analyzed for mutations. The median age of onset was 6 months (range: 2-17 months). Dogs had 5 to more than 50 lesions characterized as nodules, plaques, and papules. Seven dogs were pruritic. Clinical staging in 2 dogs did not reveal visceral involvement. No dogs had systemic illnesses at diagnosis. Histologically, CM was similar to cutaneous mast cell tumor (cMCT). Two dogs had neoplasms classified as high-grade/grade II while 6 dogs had low-grade/grade II neoplasms. No dogs had mutations in exons 8 and 11. Treatment included antihistamines (8/8), corticosteroids (7/8), lokivetmab (3/8), and toceranib (1/8). Six dogs were alive with lesions at the end of the study with a median follow-up time of 898 days, while 2 dogs were euthanized. In dogs with high-grade/grade II neoplasms, one continued to develop lesions at 1922 days post-diagnosis, while the other dog was euthanized at 56 days post-diagnosis. One dog was euthanized 621 days post-diagnosis due to rupture of a neoplasm. CM occurs in young dogs and is histologically indistinguishable from cMCT. Current histologic grading systems did not apply uniformly to the dogs of the study and further studies are needed.
皮肤肥大细胞瘤(CM)是一种罕见的疾病,发生于年轻犬,其特征为多发性皮肤的肿瘤性肥大细胞增生。通过标准化调查,获得了符合纳入标准(发病年龄小于 1.5 岁,>3 个病变)的 8 只犬的临床数据。通过 Kiupel/Patnaik 分级系统对活检样本进行分类,并分析突变情况。发病年龄中位数为 6 个月(范围:2-17 个月)。犬有 5 到 50 多个病变,表现为结节、斑块和丘疹。7 只犬有瘙痒症状。2 只犬的临床分期未显示内脏受累。诊断时无犬患有全身性疾病。组织学上,CM 与皮肤肥大细胞瘤(cMCT)相似。2 只犬的肿瘤被归类为高级/二级,而 6 只犬的肿瘤为低级/二级。没有犬在 8 号和 11 号外显子中发生突变。治疗包括使用抗组胺药(8/8)、皮质类固醇(7/8)、洛维莫司他(3/8)和托西尼莫单抗(1/8)。6 只犬在研究结束时仍有病变,且存活,中位随访时间为 898 天,而 2 只犬被安乐死。在高级/二级肿瘤的犬中,一只犬在诊断后 1922 天继续出现病变,另一只犬在诊断后 56 天被安乐死。一只犬在诊断后 621 天因肿瘤破裂而被安乐死。CM 发生于年轻犬,且在组织学上与 cMCT 无法区分。目前的组织学分级系统在本研究的犬中不能统一应用,需要进一步研究。